网站标志
导航菜单
购物车
购物车 0 件商品 | 查看购物车 | 我的订单 | 我的积分 | 会员中心
当前日期时间
当前时间:
商品搜索
商品搜索:
价格
点评详情
点评详情
发布于:2018-6-14 20:23:40  访问:6 次 回复:0 篇
版主管理 | 推荐 | 删除 | 删除并扣分
F Critical Care Medicine. Crit Care Med. 2004;32:S8 ten.
Breast U-73122 biological activity cancer Analysis (2015) 17:100 DOI 10.1186/s13058-015-0611-RESEARCH ARTICLEOpen AccessTreatment with insulin (analogues) and breast cancer risk in diabetics; a systematic assessment and meta-analysis of in vitro, animal and human evidenceHeleen K Bronsveld1,6, Bas ter Braak2, stein Karlstad3, Peter Vestergaard4, Jakob Starup-Linde4,5, s16050619 Marloes T Bazelier6, Marie L De Bruin6, Anthonius de Boer6, Christine L E Siezen7, Bob van de Water2, Jan Willem van der Laan2,7,8 and Marjanka K Schmidt1*AbstractIntroduction: Many studies have suggested that anti-diabetic insulin analogue remedy could improve cancer danger. Insulin AspB10 showed mitogenic properties CPM.0000000000000108 in vitro and in animal studies. Glargine was the only clinically offered insulin analogue for 19420889.2016.1155010 which an enhanced proliferative prospective was identified in breast cancer cell lines. Nevertheless, the pooled analysis of 13 epidemiological studies did not show proof for an association in between insulin glargine treatment and an increased breast cancer threat (HR 1.04; 95 CI 0.91-1.17; p=0.49) versus no glargine in patients with diabetes mellitus. It has to be taken into account that the number of animal studies was limited, and epidemiological studies have been underpowered and suffered from methodological limitations. Conclusion: There is no compelling proof that any clinically offered insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. General, the information suggests that insulin treatment isn‘t HPI-4 supplier involved in breast tumour initiation, but may possibly induce breast tumour progression by up regulating mitogenic signalling pathways.* Correspondence: mk.schmidt@nki.nl Equal contributors 1 Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands Complete list of author info is offered at the end on the short article?2015 Bronsveld et al. Open Access This short article is distributed below the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give acceptable credit to the original author(s) as well as the source, present a hyperlink to the Inventive Commons license, and indicate if alterations have been created. The Inventive Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the information made readily available within this write-up, unless otherwise stated.Bronsveld et al.Bronsveld et al.
F Critical Care Medicine. Crit Care Med. 2004;32:S8 10.
Bronsveld et al. Breast Cancer Investigation (2015) 17:100 DOI ten.1186/s13058-015-0611-RESEARCH ARTICLEOpen AccessTreatment with insulin (analogues) and breast cancer danger in diabetics; a systematic critique and meta-analysis of in vitro, animal and human evidenceHeleen K Bronsveld1,six, Bas ter Braak2, stein Karlstad3, Peter Vestergaard4, Jakob Starup-Linde4,5, s16050619 Marloes T Bazelier6, Marie L De Bruin6, Anthonius de Boer6, Christine L E Siezen7, Bob van de Water2, Jan Willem van der Laan2,7,eight and Marjanka K Schmidt1*AbstractIntroduction: Quite a few studies have recommended that anti-diabetic insulin analogue treatment may well enhance cancer threat. The aim of this study was to critique the postulated association between insulin and insulin analogue therapy and breast cancer development, and plausible mechanisms. Method: A systematic literature search was performed on breast cell-line, animal and human studies working with the essential words `insulin analogue‘ and `breast neoplasia‘ in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases.
共0篇回复 每页10篇 页次:1/1
共0篇回复 每页10篇 页次:1/1
我要回复
回复内容
验 证 码
看不清?更换一张
匿名发表 
脚注信息
Copyright (C) 2015-2016 All Rights Reserved. 光明云南石斛商城管理系统 版权所有   滇ICP备11005439号-1
服务时间:周一至周日 09:00 — 18:00  全国订购及服务热线:0691-5161027 
联系地址:云南省西双版纳傣族自治州勐海县工业园区   邮政编码:666200